Evidence Hub

Effectiveness and safety of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children

Azadeh Issapour, S. Crook, M. Hite, E. Rosenzweig, B. Frank, D. Ivy, U. Krishnan

Journal of the American College of Cardiology, 2020

Abstract

The AMBITION trial revealed lower risk of clinical failure events with ambrisentan and tadalafil combination as compared to monotherapy alone in adults. We aimed to describe the safety and efficacy of this combination therapy in children with PAH.

Retrospective observational study including

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free